Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-03-05

AUTHORS

Brian I. Rini, David I. Quinn, Michael Baum, Laura S. Wood, Jamal Tarazi, Brad Rosbrook, Lillian Shahied Arruda, Laura Cisar, W. Gregory Roberts, Sinil Kim, Robert J. Motzer

ABSTRACT

Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axitinib or sorafenib in the AXIS trial. AXIS was a randomized phase III study of axitinib versus sorafenib in patients with metastatic RCC following failure of one prior systemic regimen. Patients with uncontrolled hypertension were excluded, but patients with hypertension controlled with antihypertensive medication were allowed to participate. Guidelines for hypertension management included adjustment or addition of antihypertensive medications and/or axitinib or sorafenib dose reductions, interruptions, or discontinuations. Treatment-emergent all-causality hypertension occurred in 145 (40.4 %) axitinib-treated patients (N = 359) and 103 (29.0 %) sorafenib-treated patients (N = 355), with grade 3 hypertension reported in 55 (15.3 %) and 38 (10.7 %) patients, respectively, and grade 4 hypertension reported in one (0.3 %) patient in each arm. Hypertension-related events led to axitinib dose interruptions (n = 46; 12.8 %), dose reductions (n = 16; 4.5 %), or discontinuations (n = 1; 0.3 %). Approximately 50 % of axitinib-treated patients with grade 3 or 4 hypertension continued treatment for ≥ 9 months. Hypertension-related sequelae occurred in <1 % of axitinib-treated patients. Hypertension was more frequently observed during treatment with axitinib than sorafenib in patients with RCC, but axitinib-induced hypertension rarely led to treatment discontinuation or cardiovascular sequelae. Recommendations for monitoring blood pressure and managing hypertension during axitinib therapy are presented. More... »

PAGES

45-53

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-014-0307-z

DOI

http://dx.doi.org/10.1007/s11523-014-0307-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004914359

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24595903


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Axitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sorafenib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rini", 
        "givenName": "Brian I.", 
        "id": "sg:person.01113325143.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baum", 
        "givenName": "Michael", 
        "id": "sg:person.01264447017.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264447017.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Laura S.", 
        "id": "sg:person.010243623117.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010243623117.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Oncology, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pfizer Oncology, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tarazi", 
        "givenName": "Jamal", 
        "id": "sg:person.01222051212.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222051212.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Oncology, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pfizer Oncology, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosbrook", 
        "givenName": "Brad", 
        "id": "sg:person.0750542406.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750542406.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Collegeville, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Collegeville, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arruda", 
        "givenName": "Lillian Shahied", 
        "id": "sg:person.01000536776.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000536776.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Oncology, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Oncology, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cisar", 
        "givenName": "Laura", 
        "id": "sg:person.0636507256.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636507256.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Safety Strategy Risk Management, Groton, CT, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pfizer Safety Strategy Risk Management, Groton, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roberts", 
        "givenName": "W. Gregory", 
        "id": "sg:person.01300721000.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300721000.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Oncology, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pfizer Oncology, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Sinil", 
        "id": "sg:person.0600257665.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600257665.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Motzer", 
        "givenName": "Robert J.", 
        "id": "sg:person.01234500340.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11912-012-0242-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044847163", 
          "https://doi.org/10.1007/s11912-012-0242-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11906-007-0058-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015839874", 
          "https://doi.org/10.1007/s11906-007-0058-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-012-9796-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042595180", 
          "https://doi.org/10.1007/s10637-012-9796-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-03-05", 
    "datePublishedReg": "2014-03-05", 
    "description": "Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axitinib or sorafenib in the AXIS trial. AXIS was a randomized phase III study of axitinib versus sorafenib in patients with metastatic RCC following failure of one prior systemic regimen. Patients with uncontrolled hypertension were excluded, but patients with hypertension controlled with antihypertensive medication were allowed to participate. Guidelines for hypertension management included adjustment or addition of antihypertensive medications and/or axitinib or sorafenib dose reductions, interruptions, or discontinuations. Treatment-emergent all-causality hypertension occurred in 145 (40.4\u00a0%) axitinib-treated patients (N\u2009=\u2009359) and 103 (29.0\u00a0%) sorafenib-treated patients (N\u2009=\u2009355), with grade 3 hypertension reported in 55 (15.3\u00a0%) and 38 (10.7\u00a0%) patients, respectively, and grade 4 hypertension reported in one (0.3\u00a0%) patient in each arm. Hypertension-related events led to axitinib dose interruptions (n\u2009=\u200946; 12.8\u00a0%), dose reductions (n\u2009=\u200916; 4.5\u00a0%), or discontinuations (n\u2009=\u20091; 0.3\u00a0%). Approximately 50\u00a0% of axitinib-treated patients with grade 3 or 4 hypertension continued treatment for \u2265 9\u00a0months. Hypertension-related sequelae occurred in <1\u00a0% of axitinib-treated patients. Hypertension was more frequently observed during treatment with axitinib than sorafenib in patients with RCC, but axitinib-induced hypertension rarely led to treatment discontinuation or cardiovascular sequelae. Recommendations for monitoring blood pressure and managing hypertension during axitinib therapy are presented.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11523-014-0307-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "renal cell carcinoma", 
      "hypertension-related events", 
      "AXIS trial", 
      "antihypertensive medications", 
      "cell carcinoma", 
      "dose reduction", 
      "randomized phase III study", 
      "metastatic renal cell carcinoma", 
      "advanced renal cell carcinoma", 
      "vascular endothelial growth factor (VEGF) pathway", 
      "endothelial growth factor pathway", 
      "prior systemic regimen", 
      "sorafenib-treated patients", 
      "grade 3 hypertension", 
      "grade 4 hypertension", 
      "phase III study", 
      "sorafenib dose reduction", 
      "growth factor pathways", 
      "systemic regimen", 
      "uncontrolled hypertension", 
      "dose interruption", 
      "cardiovascular sequelae", 
      "axitinib therapy", 
      "treatment discontinuation", 
      "III study", 
      "blood pressure", 
      "hypertension management", 
      "hypertension", 
      "grade 3", 
      "patients", 
      "axitinib", 
      "discontinuation", 
      "factor pathway", 
      "sorafenib", 
      "medications", 
      "sequelae", 
      "carcinoma", 
      "trials", 
      "treatment", 
      "regimen", 
      "therapy", 
      "months", 
      "interruption", 
      "inhibitors", 
      "events", 
      "guidelines", 
      "reduction", 
      "failure", 
      "arm", 
      "pathway", 
      "adjustment", 
      "management", 
      "recommendations", 
      "study", 
      "analysis", 
      "pressure", 
      "axis", 
      "addition"
    ], 
    "name": "Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial", 
    "pagination": "45-53", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004914359"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-014-0307-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24595903"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-014-0307-z", 
      "https://app.dimensions.ai/details/publication/pub.1004914359"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_619.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11523-014-0307-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-014-0307-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-014-0307-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-014-0307-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-014-0307-z'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      21 PREDICATES      100 URIs      89 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-014-0307-z schema:about N000d2a2045b84da2862c23a991e9f0a4
2 N0c5027f656b54887a72ce9c3199c3c3c
3 N10b1bca5c70947ee89ad01d691e19c91
4 N13649560a9cc458ba18fb657f60e78f9
5 N2a0f436fe81b44809176e348b68420a6
6 N49aa3c5828944b73b6340d5acb9b7c90
7 N5caf9026b9aa46eeb65dacdcf840fad5
8 N7303ca2351dc49e298ffdf0a7e47562a
9 N7b16967912d74f9db9b29ca39783596b
10 N8fc7e4a73e984f75af02e4408c118609
11 Na206d51fb4fd48c9bc6bb14f00ab8b1e
12 Na5d2a22cfe9b417ebf69fd1baa57b656
13 Nac300aa5b43b4828a76ef7c4971de451
14 Ncd79208f6c4f4eea81799aa3d6b23803
15 anzsrc-for:11
16 anzsrc-for:1102
17 schema:author Ndbed36e3ba394f2da1ec2f5891d56262
18 schema:citation sg:pub.10.1007/s10637-012-9796-8
19 sg:pub.10.1007/s11906-007-0058-7
20 sg:pub.10.1007/s11912-012-0242-z
21 schema:datePublished 2014-03-05
22 schema:datePublishedReg 2014-03-05
23 schema:description Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axitinib or sorafenib in the AXIS trial. AXIS was a randomized phase III study of axitinib versus sorafenib in patients with metastatic RCC following failure of one prior systemic regimen. Patients with uncontrolled hypertension were excluded, but patients with hypertension controlled with antihypertensive medication were allowed to participate. Guidelines for hypertension management included adjustment or addition of antihypertensive medications and/or axitinib or sorafenib dose reductions, interruptions, or discontinuations. Treatment-emergent all-causality hypertension occurred in 145 (40.4 %) axitinib-treated patients (N = 359) and 103 (29.0 %) sorafenib-treated patients (N = 355), with grade 3 hypertension reported in 55 (15.3 %) and 38 (10.7 %) patients, respectively, and grade 4 hypertension reported in one (0.3 %) patient in each arm. Hypertension-related events led to axitinib dose interruptions (n = 46; 12.8 %), dose reductions (n = 16; 4.5 %), or discontinuations (n = 1; 0.3 %). Approximately 50 % of axitinib-treated patients with grade 3 or 4 hypertension continued treatment for ≥ 9 months. Hypertension-related sequelae occurred in <1 % of axitinib-treated patients. Hypertension was more frequently observed during treatment with axitinib than sorafenib in patients with RCC, but axitinib-induced hypertension rarely led to treatment discontinuation or cardiovascular sequelae. Recommendations for monitoring blood pressure and managing hypertension during axitinib therapy are presented.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N9be17d29df0a49f7911484f0c01eba7b
27 Ne4a79eb548584af699dc0e6bc79e5e1c
28 sg:journal.1036678
29 schema:keywords AXIS trial
30 III study
31 addition
32 adjustment
33 advanced renal cell carcinoma
34 analysis
35 antihypertensive medications
36 arm
37 axis
38 axitinib
39 axitinib therapy
40 blood pressure
41 carcinoma
42 cardiovascular sequelae
43 cell carcinoma
44 discontinuation
45 dose interruption
46 dose reduction
47 endothelial growth factor pathway
48 events
49 factor pathway
50 failure
51 grade 3
52 grade 3 hypertension
53 grade 4 hypertension
54 growth factor pathways
55 guidelines
56 hypertension
57 hypertension management
58 hypertension-related events
59 inhibitors
60 interruption
61 management
62 medications
63 metastatic renal cell carcinoma
64 months
65 pathway
66 patients
67 phase III study
68 pressure
69 prior systemic regimen
70 randomized phase III study
71 recommendations
72 reduction
73 regimen
74 renal cell carcinoma
75 sequelae
76 sorafenib
77 sorafenib dose reduction
78 sorafenib-treated patients
79 study
80 systemic regimen
81 therapy
82 treatment
83 treatment discontinuation
84 trials
85 uncontrolled hypertension
86 vascular endothelial growth factor (VEGF) pathway
87 schema:name Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
88 schema:pagination 45-53
89 schema:productId N7565b32de86241dbb2327b436d0b93cb
90 Na00d3cfb6ff94a9db00e9f32b478e87b
91 Nae15475873b848ee8de890b6b4c84c3c
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004914359
93 https://doi.org/10.1007/s11523-014-0307-z
94 schema:sdDatePublished 2022-10-01T06:39
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N97a60cd8546f4960bee408fe4601f402
97 schema:url https://doi.org/10.1007/s11523-014-0307-z
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N000d2a2045b84da2862c23a991e9f0a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Hypertension
103 rdf:type schema:DefinedTerm
104 N0794658f2ab34be48b18de915be32f8b rdf:first sg:person.0600257665.44
105 rdf:rest N24ed9508c53147ccbd788a5b68c84a6b
106 N0c5027f656b54887a72ce9c3199c3c3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Carcinoma, Renal Cell
108 rdf:type schema:DefinedTerm
109 N10b1bca5c70947ee89ad01d691e19c91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Niacinamide
111 rdf:type schema:DefinedTerm
112 N13649560a9cc458ba18fb657f60e78f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Female
114 rdf:type schema:DefinedTerm
115 N24ed9508c53147ccbd788a5b68c84a6b rdf:first sg:person.01234500340.18
116 rdf:rest rdf:nil
117 N2a0f436fe81b44809176e348b68420a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Sorafenib
119 rdf:type schema:DefinedTerm
120 N32149d2af4a14d7c9b8a218691e8b281 rdf:first sg:person.01013134010.15
121 rdf:rest Na2a91aa29fbb437ab61f8e1ca23fff6b
122 N49aa3c5828944b73b6340d5acb9b7c90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Humans
124 rdf:type schema:DefinedTerm
125 N4f05a97f9e464ec3b4e83532e0eeee28 rdf:first sg:person.01300721000.30
126 rdf:rest N0794658f2ab34be48b18de915be32f8b
127 N5caf9026b9aa46eeb65dacdcf840fad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Indazoles
129 rdf:type schema:DefinedTerm
130 N7303ca2351dc49e298ffdf0a7e47562a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Middle Aged
132 rdf:type schema:DefinedTerm
133 N7565b32de86241dbb2327b436d0b93cb schema:name doi
134 schema:value 10.1007/s11523-014-0307-z
135 rdf:type schema:PropertyValue
136 N7b16967912d74f9db9b29ca39783596b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antineoplastic Agents
138 rdf:type schema:DefinedTerm
139 N8fc7e4a73e984f75af02e4408c118609 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Imidazoles
141 rdf:type schema:DefinedTerm
142 N97a60cd8546f4960bee408fe4601f402 schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 N9be17d29df0a49f7911484f0c01eba7b schema:volumeNumber 10
145 rdf:type schema:PublicationVolume
146 Na00d3cfb6ff94a9db00e9f32b478e87b schema:name dimensions_id
147 schema:value pub.1004914359
148 rdf:type schema:PropertyValue
149 Na206d51fb4fd48c9bc6bb14f00ab8b1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Kidney Neoplasms
151 rdf:type schema:DefinedTerm
152 Na2a91aa29fbb437ab61f8e1ca23fff6b rdf:first sg:person.01264447017.88
153 rdf:rest Nfa04fdecc716422a816abd627c5a0b9f
154 Na5d2a22cfe9b417ebf69fd1baa57b656 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Axitinib
156 rdf:type schema:DefinedTerm
157 Na901ed93347c40bf9def801b74a7db3e rdf:first sg:person.01222051212.97
158 rdf:rest Nfe0928e5aa8c49e98facfbd812a4427b
159 Nac300aa5b43b4828a76ef7c4971de451 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Phenylurea Compounds
161 rdf:type schema:DefinedTerm
162 Nae15475873b848ee8de890b6b4c84c3c schema:name pubmed_id
163 schema:value 24595903
164 rdf:type schema:PropertyValue
165 Nb6a9b8827fe34b819f1214880b583b46 rdf:first sg:person.01000536776.64
166 rdf:rest Nf7c1564e84da44f189eb08c4f9320569
167 Ncd79208f6c4f4eea81799aa3d6b23803 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Male
169 rdf:type schema:DefinedTerm
170 Ndbed36e3ba394f2da1ec2f5891d56262 rdf:first sg:person.01113325143.17
171 rdf:rest N32149d2af4a14d7c9b8a218691e8b281
172 Ne4a79eb548584af699dc0e6bc79e5e1c schema:issueNumber 1
173 rdf:type schema:PublicationIssue
174 Nf7c1564e84da44f189eb08c4f9320569 rdf:first sg:person.0636507256.57
175 rdf:rest N4f05a97f9e464ec3b4e83532e0eeee28
176 Nfa04fdecc716422a816abd627c5a0b9f rdf:first sg:person.010243623117.05
177 rdf:rest Na901ed93347c40bf9def801b74a7db3e
178 Nfe0928e5aa8c49e98facfbd812a4427b rdf:first sg:person.0750542406.97
179 rdf:rest Nb6a9b8827fe34b819f1214880b583b46
180 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
181 schema:name Medical and Health Sciences
182 rdf:type schema:DefinedTerm
183 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
184 schema:name Cardiorespiratory Medicine and Haematology
185 rdf:type schema:DefinedTerm
186 sg:journal.1036678 schema:issn 1776-2596
187 1776-260X
188 schema:name Targeted Oncology
189 schema:publisher Springer Nature
190 rdf:type schema:Periodical
191 sg:person.01000536776.64 schema:affiliation grid-institutes:grid.410513.2
192 schema:familyName Arruda
193 schema:givenName Lillian Shahied
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000536776.64
195 rdf:type schema:Person
196 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
197 schema:familyName Quinn
198 schema:givenName David I.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
200 rdf:type schema:Person
201 sg:person.010243623117.05 schema:affiliation grid-institutes:grid.239578.2
202 schema:familyName Wood
203 schema:givenName Laura S.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010243623117.05
205 rdf:type schema:Person
206 sg:person.01113325143.17 schema:affiliation grid-institutes:grid.239578.2
207 schema:familyName Rini
208 schema:givenName Brian I.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17
210 rdf:type schema:Person
211 sg:person.01222051212.97 schema:affiliation grid-institutes:None
212 schema:familyName Tarazi
213 schema:givenName Jamal
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222051212.97
215 rdf:type schema:Person
216 sg:person.01234500340.18 schema:affiliation grid-institutes:grid.51462.34
217 schema:familyName Motzer
218 schema:givenName Robert J.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
220 rdf:type schema:Person
221 sg:person.01264447017.88 schema:affiliation grid-institutes:grid.51462.34
222 schema:familyName Baum
223 schema:givenName Michael
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264447017.88
225 rdf:type schema:Person
226 sg:person.01300721000.30 schema:affiliation grid-institutes:None
227 schema:familyName Roberts
228 schema:givenName W. Gregory
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300721000.30
230 rdf:type schema:Person
231 sg:person.0600257665.44 schema:affiliation grid-institutes:None
232 schema:familyName Kim
233 schema:givenName Sinil
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600257665.44
235 rdf:type schema:Person
236 sg:person.0636507256.57 schema:affiliation grid-institutes:grid.410513.2
237 schema:familyName Cisar
238 schema:givenName Laura
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636507256.57
240 rdf:type schema:Person
241 sg:person.0750542406.97 schema:affiliation grid-institutes:None
242 schema:familyName Rosbrook
243 schema:givenName Brad
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750542406.97
245 rdf:type schema:Person
246 sg:pub.10.1007/s10637-012-9796-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042595180
247 https://doi.org/10.1007/s10637-012-9796-8
248 rdf:type schema:CreativeWork
249 sg:pub.10.1007/s11906-007-0058-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015839874
250 https://doi.org/10.1007/s11906-007-0058-7
251 rdf:type schema:CreativeWork
252 sg:pub.10.1007/s11912-012-0242-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1044847163
253 https://doi.org/10.1007/s11912-012-0242-z
254 rdf:type schema:CreativeWork
255 grid-institutes:None schema:alternateName Pfizer Oncology, San Diego, CA, USA
256 Pfizer Safety Strategy Risk Management, Groton, CT, USA
257 schema:name Pfizer Oncology, San Diego, CA, USA
258 Pfizer Safety Strategy Risk Management, Groton, CT, USA
259 rdf:type schema:Organization
260 grid-institutes:grid.239578.2 schema:alternateName Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA
261 schema:name Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA
262 rdf:type schema:Organization
263 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, Collegeville, PA, USA
264 Pfizer Oncology, New York, NY, USA
265 schema:name Pfizer Inc, Collegeville, PA, USA
266 Pfizer Oncology, New York, NY, USA
267 rdf:type schema:Organization
268 grid-institutes:grid.42505.36 schema:alternateName University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
269 schema:name University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
270 rdf:type schema:Organization
271 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan-Kettering Cancer Center, New York, NY, USA
272 schema:name Memorial Sloan-Kettering Cancer Center, New York, NY, USA
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...